Analysts await BIND Therapeutics, Inc. (NASDAQ:BIND) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.56 EPS, down 21.43% or $0.12 from last year’s $-0.44 per share.

At the moment 4 analysts are watching BIND Therapeutics, Inc. (NASDAQ:BIND), 1 rate it “Buy”, 0 “Outperform”, 3 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 4 analysts have a mean sales target of 3.71 million. For the quarter ending Sep-16, 4 analysts have a mean sales target of 3.22 million whilst for the year ending Dec-16, 4 analysts have a mean target of 14.00 million.

In terms of earnings per share, 3 analysts have a -0.39 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 3 analysts have a -0.32 EPS mean target and for the quarter ending Sep-16 there are 4 estimates of -1.67 EPS.

The biggest institutional shareholders in BIND Therapeutics, Inc. include Polaris Venture Management Co. V,LLC which owns 2 million shares in the company valued at $4.62 million. Heights Capital Management Inc is the second biggest holder with 1 million shares currently valued at 9.45 million whilst Sabby Management LLC has 821 K million shares valued at 1.88 million.

Total shares held by institutions as of the most recent company filings are 6,240,105 with a reported 215,107 bought and 591,728 sold. These holdings make up 29.87% of the company’s outstanding shares.

The stock decreased 13.64% or $0.09 during the last trading session, hitting $0.69. BIND Therapeutics, Inc. (NASDAQ:BIND) has fallen 636.23% over the past 6 months and is downtrending.